Edesa Biotech(US:EDSA)2025-12-12 21:25Financial Performance - For the fiscal year ended September 30, 2025, Edesa reported a net loss of $7.2 million, or $1.27 per common share, compared to a net loss of $6.2 million, or $1.93 per common share for the previous year[6]. - Total operating expenses increased by $0.9 million to $7.9 million for the year ended September 30, 2025, compared to $7.0 million for the prior year[5]. - Total other income decreased by $0.1 million to $0.7 million for the year ended September 30, 2025, primarily due to a decrease in interest income[5]. Research and Development - Research and development expenses rose by $0.8 million to $3.7 million for the year ended September 30, 2025, primarily due to increased manufacturing-related activities[8]. - A Phase 3 study of paridiprubart met primary and secondary endpoints with statistical significance, and Edesa is exploring development partnerships for this asset[3]. - The company initiated manufacturing activities for a Phase 2 study of EB06, with recruitment expected to begin by midyear 2026[3]. Financial Position - Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million as of September 30, 2025[7]. - Edesa's balance sheet was strengthened, and the Canadian government funding agreement was extended to support manufacturing and development for the respiratory program[4]. Strategic Initiatives - The company plans to participate in one-on-one meetings during JP Morgan week starting January 12, 2026, to engage with potential partners[9]. - Edesa is focused on executing the Phase 2 vitiligo study, advancing respiratory assets toward commercialization, and expanding manufacturing capacity[4].